Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Dual Targeting of SLAMF-7 and CD38 - A Ph2 Study of Isatuximab, Elotuzumab, Pomalidomide and Dexamethasone in R/R MM"
By
Insights from 2023 ASH Annual Meeting
FEATURING
Binod Dhakal
By
Insights from 2023 ASH Annual Meeting
FEATURING
Binod Dhakal
Login to view comments.
Click here to Login